Introduction
Established in 2002, Hangzhou FST Pharmaceutical focuses on advanced intermediates, APIs, and nutraceuticals. In 2022, it was acquired by Shanghai Eyougene Biotechnology, founded by top Fudan University graduates. Eyougene excels in digital CDMO services for advanced intermediates and new materials. The group has R&D centers in Shanghai, Xi'an, and Wuhan, with 382 employees, including 169 R&D and QA professionals. The main products include cardiovascular, gastrointestinal, and weight control products.
Located in Jiande Hangzhou, the factory complies with GMP and holds ISO9001:2000, ISO14001, and OHSAS18001 certifications. Eyougene is committed to life science innovation for human health.
Here is the profile of Eyougene and FST. You can find the introduction of company, technology, products,production system and business partners.
Hangzhou Fst Pharmaceutical Co.,Ltd
-
CN
-
2015On CPHI since
-
3Certificates
-
250 - 499Employees
Other Content from Hangzhou Fst Pharmaceutical Co.,Ltd ()
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance